1 - 6 of 6 results
lipoprotein cell close up

Lipoprotein(a) Learning Module

An Adaptive Learning Experience Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE CreditThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Lipoprotein(a) is a genetically determined LDL-C like particle that is uniquely proatherogenic, prothrombotic, and proinflammatory. While emerging therapies are on the horizon, there are no current FDA approved medicinal treatment options for Lp(a). Understanding the prevalence and need to test for Lp(a) will help your patients mitigate potential cardiovascular risks via lifestyle modification and informing clinical practice. This interactive module will cover: • The differences between LDL-C and Lp(a) • Testing and incidence of Lp(a), as well as associated diseases • Cardiovascular risk and risk-enhancing factors that can lead to cardiovascular events • Lifestyle management and risk factor mitigation


Tile overview image

Atherosclerotic Cardiovascular Disease (ASCVD)

An Interactive Learning Experience Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE CreditThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death globally. An effort to reduce the mortality risk to patients must include prevention and optimal treatment of patients with the greatest individual and combined risk factors including hypertension and hyperlipidemia, as well as other comorbid conditions that contribute to cardiovascular health.


lipoprotein cell close up

Lipoprotein(a) Learning Module

An Adaptive Learning Experience Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE CreditThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Lipoprotein(a) is a genetically determined LDL-C like particle that is uniquely proatherogenic, prothrombotic, and proinflammatory. While emerging therapies are on the horizon, there are no current FDA approved medicinal treatment options for Lp(a). Understanding the prevalence and need to test for Lp(a) will help your patients mitigate potential cardiovascular risks via lifestyle modification and informing clinical practice. This interactive module will cover: • The differences between LDL-C and Lp(a) • Testing and incidence of Lp(a), as well as associated diseases • Cardiovascular risk and risk-enhancing factors that can lead to cardiovascular events • Lifestyle management and risk factor mitigation


Physician checking elder patient hear with stethoscope
1.5 CME CREDITS

Updates in Preventive Cardiology and Aortic Disease

1.50 CME/MOC
1.50 AANP | 0.50 Pharmacology

Join Dr. Ty Gluckman and Dr. Rachel Bond as they discuss important areas in cardiology where primary care clinicians can make a big difference. These topics include recognizing aortic and thoracic aneurisms, including screening in appropriate populations. Also included are updates in lipids management.


0.25 CME CREDIT

Time to Recommend the Use of Salt Substitutes for CVD Prevention? - Frankly Speaking EP 250

Guest: Robert A. Baldor, MD, FAAFPMusic Credit: Richard Onorato

0.25 CME

While the data conflict on how much sodium intake is optimal for preventing cardiovascular disease, it is clear that daily salt intake for most Americans exceeds what is recommended. However, restricting salt intake on an individual or on a public health level has been controversial. An interesting alternative is the use of salt substitutes, which can help to decrease sodium intake while increasing potassium intake, and both have been associated with lowering blood pressure. Join us to hear a discussion on the results of the recently published studies on salt and cardiovascular disease, along with an overview of the Salt Substitute and Stroke Study (SSaSS).


0.5 CME CREDIT

Cardiovascular risk factors leading to the leading causes of death in the United States have their origins in the pediatric age group. This session is intended to give primary care providers a high level view of screening and management for cardio-metabolic risk factors in the pediatric age group based on the most up-to-date guidelines.